xmlns:atom="http://www.w3.org/2005/Atom" xmlns:atom="http://www.w3.org/2005/Atom"
4.—(1) The NHS (Wales) Act is amended as follows.
(2) In section 46 (GMS contracts: prescription of drugs, etc)—
(a)in subsection (3), for “Community marketing authorization or United Kingdom” substitute “ UK ”;
(b)for subsection (4) substitute—
“(4) “UK marketing authorisation” has the meaning given by regulation 8(1) of the Human Medicines Regulations 2012 (S.I. 2012/1916).”.
(3) Omit the following provisions—
(a)section 6A (reimbursement of cost of services provided in another EEA state) M1;
(b)section 6B (prior authorisation for the purposes of section 6A) M2;
(c)section 6BA (reimbursement of cost of services provided in another EEA state where expenditure incurred on or after 25 October 2013) M3;
(d)section 6BB (prior authorisation for the purposes of section 6BA) M4;
(e)section 131(a)(ii) (payment of travelling expenses) M5;
(f)the definition of “Regulation (EC) No. 883/2004” in section 206(1) (interpretation) M6 except in so far as it relates to section 131(a)(iii).
Commencement Information
I1Reg. 4 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1(1)
Marginal Citations
M1Section 6A was inserted by S.I. 2010/915 and amended by S.I. 2013/2269.
M2Section 6B was inserted by S.I. 2010/915 and amended by S.I. 2013/2269.
M3Section 6BA was inserted by S.I. 2013/2269.
M4Section 6BB was inserted by S.I. 2013/2269.
M5Section 131(a) was substituted by S.I. 2010/915 and amended by S.I. 2013/2269.
M6The definition was inserted by S.I. 2010/915.